Skip to main content

Mucus Management in Urinary Diversions

Intestinal segments transposed into the urinary tract continue to produce mucus; in a 43-patient randomized crossover trial, 67% reported no decrease in mucus production over time, with mucin output of 65 mg/24 h after ileal conduit and 60 mg/24 h after bladder reconstruction.[2] Mucus can obstruct catheters and may serve as a stone nidus in augmented bladders.[1][3][32] Case reports describe obstructive AKI and ileal-neobladder rupture after mucus plugging.[9][10] Saline irrigation mechanically clears mucus from catheterized neobladders; a 43-patient randomized crossover trial found no mucin-output or viscosity benefit from NAC, aspirin, or ranitidine.[25][2]

This article distinguishes mechanical irrigation from mucolytic agents with uncertain clinical benefit and small positive perioperative octreotide trials. Oral bicarbonate treats systemic acidosis, a separate indication. For the acid–base management, see Urinary acidifiers; for B12 considerations after ileal-segment diversion, see Vitamin B12 supplementation.

The Clinical Problem​

The table covers mucus-related obstruction, stone findings after lower urinary tract reconstruction, bacterial colonization, and severe events reported after mucus plugging.[5][6][7][8][9][10][32]

ComplicationTimingMechanism
Catheter obstructionPerioperative > lifelongMucus plugs lumen of SPT or urethral catheter
UrolithiasisMonths to yearsMucus may serve as a stone nidus in augmented bladders[32]; among 99 patients treated for stones after reconstruction, lower-tract stones predominated in neobladders, continent cutaneous diversions and augments.[6]
UTILong-termA neobladder review reports that most reservoirs remain colonized with bacteria and that mucus may entrap bacteria as a host defense.[7] An uncontrolled pediatric ileocystoplasty irrigation-and-surveillance cohort reported no recurrent UTI over median 48-month follow-up.[8]
Obstructive AKIRare but severeComplete outlet obstruction; case reports of emergent hemodialysis[9]
Neobladder ruptureRare, life-threateningUrethral obstruction by mucous plug → intraperitoneal rupture[10]

Does the bowel adapt? Histology suggests partial, slow adaptation: ileal neobladder mucosa progressively flattens, with reduced mucin production after 3 years and a flat, avillous epithelium without mucin secretion predominating after 6 years.[4] In N'Dow's questionnaire, 67% of patients reported that mucus production had not decreased over time; reassess mucus and emptying over lifelong follow-up.[2]

1. Normal Saline Irrigation — The Standard​

Mechanical irrigation is the usual first approach for mucus in catheterized bowel reservoirs. The regimen depends on the reconstruction and drainage. Saline works mechanically; it flushes and dilutes mucus rather than dissolving it.[5][11]

Perioperative protocol​

Use the operating team's catheter size, route and irrigation plan. There is no universal ≥22-Fr suprapubic catheter requirement across adult or pediatric neobladders and augments. Teach gentle saline instillation and withdrawal, confirm drainage and document return. An institutional example is MSK's neobladder catheter-care protocol; do not force irrigation against resistance.[25]

In Khorrami 2017, irrigations were performed for obstruction, not on a universal schedule; control participants averaged 9.5 before discharge and 11.4 afterward.[11]

Long-term protocol​

  • Continent reservoirs and orthotopic neobladders. Discuss possible long-term catheterization and irrigation, and assess the patient’s ability to perform them before surgery. In a pediatric enterocystoplasty cohort, weekly sterile-water washouts were increased when mucus burden rose.[12][13]
  • Pediatric augmentation cystoplasty (van den Heijkant 2011). Structured bladder-irrigation plus nurse-specialist-supported surveillance programs in 28 children reported calculi in 2/28 (7%) and no recurrent UTIs over a median 48-month follow-up (range 6–87 months).[8] The program was uncontrolled.[8]
  • Encourage adequate hydration after diversion.[23]

What the evidence does and doesn't show​

  • Comparative limits. In Hensle's nonrandomized sequential reconstruction cohorts, reservoir stones occurred in 39/91 patients without routine irrigation instruction versus 3/42 after a prophylactic irrigation protocol.[31] The optimal irrigation volume and frequency are not established across reconstructions.
  • Brough 1998 pediatric enterocystoplasty cohort. All 30 children with continent diversions and 30 with augmentation alone were instructed to perform weekly sterile-water washouts; stones formed in 5/30 (17%) and 2/30 (7%), respectively. The authors found no significant reduction compared with previously published rates.[13]

2. N-Acetylcysteine (NAC) — The In-Vitro-vs-Clinical Mismatch​

NAC breaks disulfide bonds between mucin glycoproteins, reducing viscosity, a mechanism known from pulmonary secretions and transferred (optimistically) to urinary-diversion mucus.[14]

In vitro — positive​

Schrier 2002. In an in-vitro assay using mucus from one early postoperative ileal-neobladder patient, 0.5 mL of 10% NAC stock mixed with 4.5 mL mucus (approximately 1% NAC in the assay) reduced viscosity after 5 minutes at 37°C compared with water control.[15] This established the pharmacologic rationale.

Clinical — negative​

The randomized trial of NAC, aspirin and ranitidine was negative. N'Dow 2001 was a prospective, randomized, double-blind, placebo-controlled crossover trial in 43 patients (12 ileal conduit, 31 bladder reconstruction):[2]

  • NAC, aspirin, and ranitidine all failed to reduce mucin production, urine viscosity, or improve quality of life compared with placebo.
  • Positive clinical reports are anecdotal case reports and small uncontrolled series only.[1]

The framing that matters​

NAC is a mucolytic: in an in-vitro assay of mucus from one ileal-neobladder patient, it lowered viscosity.[1][3][15] In a 43-patient randomized crossover trial, the tested NAC regimen did not reduce mucin output or urine viscosity or improve quality of life versus placebo.[2] An intravesical adjunct may be considered by specialists for selected difficult mucus.

Off-label formulation safety​

Intravesical acetylcysteine is off-label. A respiratory or oral acetylcysteine label does not validate a bladder concentration, dilution or beyond-use interval. If selected, use a pharmacy-approved local preparation and protocol; do not infer a bladder dose from the 10–20% stock concentration.[1][16]

The negative randomized evidence does not support routine drug therapy for mucus burden, including a routine oral NAC prescription.[2]

3. Sodium Bicarbonate — Systemic Acidosis and Uncertain Irrigation Benefit​

Sodium bicarbonate serves two unrelated roles in diversion patients, and the evidence is lopsided.

Oral sodium bicarbonate for documented metabolic acidosis​

Intestine in contact with urine reabsorbs chloride and ammonium, causing hyperchloremic metabolic acidosis.[17][18]

  • Müller 2020. In a retrospective cohort of 345 patients entering rehabilitation after cystectomy with ileal neobladder, 200 (58.0%) had metabolic acidosis at a median 29 days after surgery. Oral sodium bicarbonate use rose from 45.2% to 86.7% over three weeks as 24-hour pad-test leakage fell.[19]
  • Miyake 2004. Severe metabolic acidosis in 10–17% of colon-neobladder and ileal-neobladder patients was fully normalized with oral bicarbonate.[20]

See Urinary acidifiers & alkalinizers for full dosing detail.

Intravesical bicarbonate for mucus — anecdotal​

No RCT has tested intravesical sodium-bicarbonate irrigation for mucus dissolution. The mechanistic rationale (alkaline pH may solubilize acidic mucins) is plausible but unproven. No standard intravesical preparation is established here; follow a verified institutional protocol if used.

4. Other Mucoregulatory Agents — What to Know​

AgentMechanismEvidenceBottom line
Octreotide (short-acting SC; Sandostatin LAR IM)Somatostatin analogue → ↓ intestinal secretionTwo small studies from one group — Khorrami 2008 (n = 40, ileal enterocystoplasty; subcutaneous octreotide 0.05 mg starting 1 hour pre-op, then every 8 h during hospitalization for up to 15 days, reduced to every 12 h at home after early discharge; mean irrigations 0.35 vs 10.35, day-3 mucus 4.4 vs 42.5 mL) and Khorrami 2017 (65 patients after cystectomy with ileal neobladders, double-blind placebo-controlled; week-1 24-h mucus 5.4 vs 21.5 mL and predischarge irrigations 2.3 vs 9.5, both p < 0.001; approximately 75% less mucus at week 1)[5][11]The 2017 study used long-acting octreotide 20 mg IM 4 wk pre-op and on the day of surgery. Off-label, not a routine recommendation
Urea 40% intravesical instillationDenatures mucin proteinsBushman 1994 small case series[21]Historical specialist use only; not a first-response instruction for an obstructed fresh reconstruction
Ranitidine 300 mg/dayH₂ blocker → ↓ goblet-cell secretion8-patient uncontrolled series showed lower urinary mucus after 10 days (1.38 → 0.39 mg/mL);[26] the only RCT was negative[2]No routine mucus-control role. A randomized crossover trial found no benefit from ranitidine; famotidine was not tested in that trial.[2] The FDA requested withdrawal of older ranitidine products in 2020 over NDMA concerns, then approved reformulated tablets in November 2025.[27][28]
AspirinCOX inhibition → ↓ PG-mediated secretionOne crossover trial found no mucus-control benefit.[2]No established mucus-control role
Gentamicin irrigationsIntravesical antibioticA pediatric post-transplant series used oral antibiotic suppression and/or gentamicin bladder irrigation; mucus outcomes and gentamicin-specific effects were not measured.[22]No established mucus-control role

Interpretation: the 2017 trial supports a short-term reduction in mucus and obstruction-related irrigations in its population.[5][11]

Practical Summary Table​

ModalityActionEvidenceRole
Normal saline irrigationMechanical flushUsual first approach for mucus in catheterized reservoirs[2][5][11]; EAU 2026 weak recommendation for stone-recurrence prevention in bladder augmentation, continent cutaneous reservoirs and neuropathic bladders without prior autonomic dysreflexia[29]. A randomized volume comparison in 75 spina bifida patients with ileal or colonic augmentation who catheterized via an abdominal stoma and were stone-free 3 months after removal of prior bladder stones found less recurrence with 240 mL daily than with 60 or 120 mL by year 7.[30]First approach for catheterized reservoirs; frequency and duration individualized
HydrationSupports urinary-tract healthPatient-page advice[23]Individualize to fluid needs
Intravesical NAC (off-label; no established bladder concentration)Mucolytic (disulfide-bond cleavage)In vitro positive; RCT negative[2][15]Selected off-label adjunct; clinical benefit uncertain
Sodium bicarbonate (oral)Correct metabolic acidosisObservational reports[19][20]Used for documented acidosis; titrate to response
Sodium bicarbonate (intravesical)Alkaline mucus solubilizationAnecdotalInstitution-specific
Octreotide LAR 20 mg IM↓ intestinal secretion2 small positive studies, one placebo-controlled RCT[5][11]Small perioperative studies; not routine
Urea 40% intravesicalMucin denaturationCase series[21]Historical specialist protocol; not routine emergency advice
Ranitidine / aspirin—No mucus benefit in a 43-patient crossover trial.[2]No routine mucus-reduction role

Perioperative Considerations​

  • Teach the prescribed catheter-irrigation technique and escalate poor return, pain, distension or absent drainage promptly. Do not force fluid into a blocked reservoir.[25]
  • A mucus plug can cause obstructive AKI or rupture. If gentle irrigation fails, obtain urgent urologic assessment to restore drainage; do not delay drainage for experimental chemical dissolution.[9][10][21]
  • Octreotide remains an off-label option supported by small studies, not a default high-risk-patient prescription.[5][11]
  • Monitor renal function and electrolytes during recovery according to clinical risk. In Müller's retrospective cohort of 345 patients after radical cystectomy and ileal neobladder construction for bladder cancer, the proportion needing oral sodium bicarbonate replacement for acidosis rose from 45.2% at the start to 86.7% at the end of three weeks of inpatient rehabilitation.[19]

Long-Term Follow-Up​

  • AUA/SUFU adult neurogenic LUTD guideline recommends lifelong annual surveillance for NLUTD patients with bowel-incorporating urinary reconstructions: focused history, exam, basic metabolic panel, and urinary-tract imaging .[24]
  • Metabolic factors affect stone prevention alongside mucus management. A selected stone-former cohort reported frequent hypocitraturia, high urine pH, low urine volume and hyperoxaluria; its percentages describe selected stone formers.[6] Evaluate metabolic abnormalities and emptying alongside the irrigation plan.
  • Hydration. Individualize fluid goals to renal or cardiac status, losses and stone risk; a fixed high-volume goal is not suitable for everyone.[23]

Practical Pearls​

  • Mechanical emptying and an individualized irrigation plan remain central; no routine mucolytic prescription has established broad benefit.[1][2]
  • Explain that mucus can persist and teach obstruction warning signs.[2][25]
  • Maintain lifelong follow-up, adapted to the reconstruction, emptying method, renal risk and patient or caregiver ability.[12][24]

See Also​

References​

1. Covert WM, Westin SN, Soliman PT, Langley GD. "The role of mucoregulatory agents after continence-preserving urinary diversion surgery." Am J Health Syst Pharm. 2012;69(6):483–486. doi:10.2146/ajhp110212

2. N'Dow J, Robson CN, Matthews JN, Neal DE, Pearson JP. "Reducing mucus production after urinary reconstruction: a prospective randomized trial." J Urol. 2001;165(5):1433–1440. doi:10.1016/s0022-5347(05)66323-9

3. N'Dow J, Pearson J, Neal D. "Mucus production after transposition of intestinal segments into the urinary tract." World J Urol. 2004;22(3):178–185. doi:10.1007/s00345-004-0436-6

4. Parenti A, Aragona F, Bortuzzo G, De Caro R, Pagano F. "Abnormal patterns of mucin secretion in ileal neobladder mucosa: evidence of preneoplastic lesion?" Eur Urol. 1999;35(2):98–101. doi:10.1159/000019826

5. Khorrami MH, Salehi P, Nouri-Mahdavi K, Ghalamkari A, Tadayyon F. "Dramatic effect of a somatostatin analogue in decreasing mucus production by the intestinal segment after enterocystoplasty." J Urol. 2008;180(6):2501–2503. doi:10.1016/j.juro.2008.08.024

6. Marien T, Robles J, Kammann TM, et al. "Characterization of urolithiasis in patients following lower urinary tract reconstruction with intestinal segments." J Endourol. 2017;31(3):217–222. doi:10.1089/end.2016.0297

7. Broderick GA, Stone AR, deVere White R. "Neobladders: clinical management and considerations for patients receiving chemotherapy." Semin Oncol. 1990;17(5):598–605. PMID 2218572

8. van den Heijkant M, Haider N, Taylor C, Subramaniam R. "Efficacy of bladder irrigation and surveillance program in prevention of urinary tract infections and bladder calculi in children with an ileocystoplasty and bladder neck repair." Pediatr Surg Int. 2011;27(7):781–785. doi:10.1007/s00383-011-2913-5

9. Singla M, Shikha D, Lee S, et al. "Ileal neobladder with mucous plugs as a cause of obstructive acute kidney injury requiring emergent hemodialysis." Am J Ther. 2016;23(4):e1099–e1101. doi:10.1097/MJT.0000000000000140

10. Haupt G, Pannek J, Knopf HJ, Schulze H, Senge T. "Rupture of ileal neobladder due to urethral obstruction by mucous plug." J Urol. 1990;144(3):740–741. doi:10.1016/s0022-5347(17)39571-x

11. Khorrami MH, Javid A, Izadpanahi MH, et al. "Efficacy of long-acting octreotide on reducing mucus production in patients with ileal neobladder." Clin Genitourin Cancer. 2017;15(1):e9–e13. doi:10.1016/j.clgc.2016.10.012

12. van Savage JG, Slaughenhoupt BL. "Approach to urinary diversion in the surgical patient." J Surg Oncol. 2000;73(1):33–38. doi:10.1002/(sici)1096-9098(200001)73:1<33::aid-jso10>3.0.co;2-z

13. Brough RJ, O'Flynn KJ, Fishwick J, Gough DC. "Bladder washout and stone formation in paediatric enterocystoplasty." Eur Urol. 1998;33(5):500–502. doi:10.1159/000019643

14. Raghu G, Berk M, Campochiaro PA, et al. "The multifaceted therapeutic role of N-acetylcysteine (NAC) in disorders characterized by oxidative stress." Curr Neuropharmacol. 2021;19(8):1202–1224. doi:10.2174/1570159X19666201230144109

15. Schrier BP, Lichtendonk WJ, Witjes JA. "The effect of N-acetyl-L-cysteine on the viscosity of ileal neobladder mucus." World J Urol. 2002;20(1):64–67. doi:10.1007/s00345-001-0234-3

16. US prescribing information. Acetylcysteine solution (inhalation/oral). DailyMed label. The labeled routes do not establish an intravesical formulation or dose.

17. Hall MC, Koch MO, McDougal WS. "Metabolic consequences of urinary diversion through intestinal segments." Urol Clin North Am. 1991;18(4):725–735. doi:10.1016/s0094-0143(21)00373-6

18. Lockhart JL, Davies R, Persky L, Figueroa TE, Ramirez G. "Acid-base changes following urinary tract reconstruction for continent diversion and orthotopic bladder replacement." J Urol. 1994;152(2 Pt 1):338–342. doi:10.1016/s0022-5347(17)32734-9

19. Müller G, Butea-Bocu M, Brock O, et al. "Association between development of metabolic acidosis and improvement of urinary continence after ileal neobladder creation." J Urol. 2020;203(3):585–590. doi:10.1097/JU.0000000000000583

20. Miyake H, Hara S, Eto H, et al. "Significance of renal function in changes in acid-base metabolism after orthotopic bladder replacement: colon neobladder compared with ileal neobladder." Int J Urol. 2004;11(2):83–87. doi:10.1111/j.1442-2042.2004.00749.x

21. Bushman W, Howards SS. "The use of urea for dissolution of urinary mucus in urinary tract reconstruction." J Urol. 1994;151(4):1036–1037. doi:10.1016/s0022-5347(17)35170-4

22. Traxel E, DeFoor W, Minevich E, et al. "Low incidence of urinary tract infections following renal transplantation in children with bladder augmentation." J Urol. 2011;186(2):667–671. doi:10.1016/j.juro.2011.03.155

23. Khosla AA, Mendhiratta N, Jatwani K. "Urinary diversion after cystectomy for bladder cancer" (JAMA Oncology Patient Page). JAMA Oncol. 2026;12(1):119. doi:10.1001/jamaoncol.2025.3644

24. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU guideline on adult neurogenic lower urinary tract dysfunction: treatment and follow-up." J Urol. 2021;206(5):1106–1113. doi:10.1097/JU.0000000000002239

25. Memorial Sloan Kettering Cancer Center. Caring for your ileal neobladder. Institutional catheter-care instructions. Accessed September 12, 2026.

26. George VK, Gee JM, Wortley MI, et al. "The effect of ranitidine on urine mucus concentration in patients with enterocystoplasty." Br J Urol. 1992;70(1):30–32. doi:10.1111/j.1464-410x.1992.tb15659.x

27. US Food and Drug Administration. "FDA requests removal of all ranitidine products (Zantac) from the market." Drug Safety Communication, April 1, 2020. Summary

28. US Food and Drug Administration. "FDA Approves Reformulated Ranitidine Following Comprehensive Safety Review." November 24, 2025. Official notice.

29. European Association of Urology. EAU Guidelines on Urolithiasis. 2026 ed., sections 6.4.5 and 6.6. Official guideline.

30. Husmann DA. "Long-term complications following bladder augmentations in patients with spina bifida: bladder calculi, perforation of the augmented bladder and upper tract deterioration." Transl Androl Urol. 2016;5(1):3–11. doi:10.3978/j.issn.2223-4683.2015.12.06

31. Hensle TW, Bingham J, Lam J, Shabsigh A. "Preventing reservoir calculi after augmentation cystoplasty and continent urinary diversion: the influence of an irrigation protocol." BJU Int. 2004;93(4):585–587. doi:10.1111/j.1464-410X.2003.04664.x

32. Khoury AE, Salomon M, Doche R, et al. "Stone formation after augmentation cystoplasty: the role of intestinal mucus." J Urol. 1997;158(3 Pt 2):1133–1137. PMID:9258156. doi:10.1016/s0022-5347(01)64404-5